ArticlePLoS pathogens2013
Immunodomination during peripheral vaccinia virus infection.
Article in PLoS pathogens, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 37 citations in OpenAlex.
- Neoantigen-Encoded Oncolytic Viruses as Personalized Cancer Vaccines.Pharmaceuticals (Basel, Switzerland) · 2026Review
- A poxvirus model reveals general correlates of antigen presentation and immunogenicity for viral CD8Science advances · 2025Article
- Vaccinia Virus: Mechanisms Supporting Immune Evasion and Successful Long-Term Protective Immunity.Viruses · 2024Review
- Enhancing the Immunogenicity of Vaccinia Virus.Viruses · 2022Article
- Article
- Direct Priming of CD8Journal of virology · 2021Article
- A natural polymorphism of Mycobacterium tuberculosis in the esxH gene disrupts immunodomination by the TB10.4-specific CD8 T cell response.PLoS pathogens · 2020Article
- Surprisingly Effective Priming of CD8Journal of virology · 2020Article
- Article
- Efficient Induction of Cytotoxic T Cells by Viral Vector Vaccination Requires STING-Dependent DC Functions.Frontiers in immunology · 2020Article
- Immunodomination of Serotype-Specific CD4+ T-Cell Epitopes Contributed to the Biased Immune Responses Induced by a Tetravalent Measles-Vectored Dengue Vaccine.Frontiers in immunology · 2020Article
- Modified Vaccinia Virus Ankara Can Induce Optimal CD8Journal of virology · 2019Article
- Influenza A Virus Infection Induces Viral and Cellular Defective Ribosomal Products Encoded by Alternative Reading Frames.Journal of immunology (Baltimore, Md. : 1950) · 2019Article
- Most viral peptides displayed by class I MHC on infected cells are immunogenic.Proceedings of the National Academy of Sciences of the United States of America · 2019Article
- IL-33 Augments Virus-Specific Memory T Cell Inflation and Potentiates the Efficacy of an Attenuated Cytomegalovirus-Based Vaccine.Journal of immunology (Baltimore, Md. : 1950) · 2019Article
- Increasing antigen presentation on HSV-1-infected cells increases lesion size but does not alter neural infection or latency.The Journal of general virology · 2018Article
- Cross-priming induces immunodomination in the presence of viral MHC class I inhibition.PLoS pathogens · 2018Article
- PD-1 Blockade Promotes Epitope Spreading in Anticancer CD8Journal of immunology (Baltimore, Md. : 1950) · 2017Article
- Pulmonary Dendritic Cell Subsets Shape the Respiratory Syncytial Virus-Specific CD8+ T Cell Immunodominance Hierarchy in Neonates.Journal of immunology (Baltimore, Md. : 1950) · 2017Article
- CD4(+) T-cell dependence of primary CD8(+) T-cell response against vaccinia virus depends upon route of infection and viral dose.Cellular & molecular immunology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Immunodominance is a fundamental property of CD8(+) T cell responses to viruses and vaccines. It had been observed that route of administration alters immunodominance after vaccinia virus (VACV) infection, but only a few epitopes were examined and no mechanism was provided. We re-visited this issue, examining a panel of 15 VACV epitopes and four routes, namely intradermal (i.d.), subcutaneous (s.c.), intraperitoneal (i.p.) and intravenous (i.v.) injection. We found that immunodominance is sharpened following peripheral routes of infection (i.d. and s.c.) compared with those that allow systemic virus dissemination (i.p. and i.v.). This increased immunodominance was demonstrated with native epitopes of VACV and with herpes simplex virus glycoprotein B when expressed from VACV. Responses to some subdominant epitopes were altered by as much as fourfold. Tracking of virus, examination of priming sites, and experiments restricting virus spread showed that priming of CD8(+) T cells in the spleen was necessary, but not sufficient to broaden responses. Further, we directly demonstrated that immunodomination occurs more readily when priming is mainly in lymph nodes. Finally, we were able to reduce immunodominance after i.d., but not i.p. infection, using a VACV expressing the costimulators CD80 (B7-1) and CD86 (B7-2), which is notable because VACV-based vaccines incorporating these molecules are in clinical trials. Taken together, our data indicate that resources for CD8(+) T cell priming are limiting in local draining lymph nodes, leading to greater immunodomination. Further, we provide evidence that costimulation can be a limiting factor that contributes to immunodomination. These results shed light on a possible mechanism of immunodomination and highlight the need to consider multiple epitopes across the spectrum of immunogenicities in studies aimed at understanding CD8(+) T cell immunity to viruses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.